阿巴西普治疗早期活动性原发性干燥综合征:ASAP-III 随机双盲安慰剂对照 3 期试验
这项单中心、随机、双盲、安慰剂对照 3 期试验纳入 80 例早期活动性原发性干燥综合征患者,比较每周皮下注射阿巴西普 125 mg 与安慰剂共 24 周的疗效与安全性。两组不良事件发生情况相似,无死亡或治疗相关严重不良事件。基于该试验,不能推荐阿巴西普作为原发性干燥综合征减少系统性疾病活动的标准治疗。
要点
- 阿巴西普 125 mg 每周皮下注射 24 周未显著改善第 24 周 ESSDAI 评分。
- 安全性方面无死亡或治疗相关严重不良事件,两组不良事件与感染发生情况相似。
核心结论
- 基于本试验,不能推荐阿巴西普作为原发性干燥综合征减少系统性疾病活动的标准治疗。
- 后续研究应评估具有特定临床表现和生物学特征的患者是否可能从阿巴西普治疗中获益。
研究设计与样本
- 单中心、随机、双盲、安慰剂对照 3 期试验,在荷兰格罗宁根大学医学中心开展。
- 纳入符合美国-欧洲共识组标准、年龄 18 岁及以上、唇腺活检阳性、诊断时间 7 年或以内且 ESSDAI 评分 5 分及以上的原发性干燥综合征患者。
- 采用计算机生成序列按既往改善病情抗风湿药使用情况分层,1:1 随机分配至阿巴西普组或安慰剂组。
- 患者每周在家皮下注射阿巴西普 125 mg 或安慰剂一次,共 24 周;主要结局为第 24 周 ESSDAI 评分的组间差异。
- 2014 年 8 月 14 日至 2018 年 8 月 23 日期间筛查 580 例患者,最终 80 例被随机分配接受研究治疗。
主要发现
- 疗效分析纳入阿巴西普组 40 例和安慰剂组 39 例(安慰剂组 1 例失访)。
- 未发生死亡或治疗相关严重不良事件。
- 阿巴西普组 40 例中 38 例(95%)发生 103 起不良事件,包括 1 起严重不良事件和 46 起感染。
- 安慰剂组 40 例中 38 例(95%)发生 87 起不良事件,包括 4 起严重不良事件和 49 起感染。
关键数值与推荐
- 纳入标准要求 ESSDAI 评分 5 分及以上、诊断时间 7 年或以内且唇腺活检阳性。
- 阿巴西普用法为每周皮下注射 125 mg,共 24 周。
临床怎么用
- 基于本试验结果,不应将阿巴西普作为原发性干燥综合征减少系统性疾病活动的标准治疗。
- 对于具有特定临床表现和生物学特征的原发性干燥综合征患者,阿巴西普的潜在获益仍需进一步研究评估。
局限性
- 本研究为单中心试验,随机分配接受研究治疗的患者共 80 例。
- 疗效分析排除了安慰剂组 1 例失访患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several small open-label studies have suggested efficacy of abatacept-a co-stimulation inhibitor-in patients with primary Sjögren's syndrome. These promising results warranted further evaluation. We therefore aimed to further assess the safety and efficacy of abatacept compared with placebo in patients with primary Sjögren's syndrome. METHODS: We did a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial at the University Medical Center Groningen (Groningen, Netherlands). We included patients with primary Sjögren's syndrome fulfilling the American-European Consensus Group criteria, aged 18 years or older, with positive salivary gland biopsies, time from diagnosis of 7 years or less, and a European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) score of 5 or more. Independent pharmacists randomly allocated patients (1:1) to either the abatacept group or placebo group using a computer-generated sequence stratified by previous use of disease-modifying anti-rheumatic drugs. Patients received at-home subcutaneous injections of abatacept (125 mg) or placebo once a week for 24 weeks. The primary outcome was the between-group difference in ESSDAI score at week 24. Efficacy was analysed in patients who received at least one drug dose and for whom post-baseline data were collected. Safety was analysed in all patients who received at least one drug dose. FINDINGS: Between Aug 14, 2014, and Aug 23, 2018, 580 patients were reviewed for eligibility, of which 80 patients were randomly assigned to receive study treatment. Efficacy was analysed in 40 patients receiving abatacept and 39 patients receiving placebo (one patient in this group was lost to follow-up). The primary outcome did not significantly differ between the treatment groups. The adjusted mean difference in ESSDAI score at week 24 between the abatacept group and placebo group was -1·3 (95% CI -4·1 to 1·6). No deaths or treatment-related serious adverse events occurred. In 38 (95%) of 40 patients in the abatacept group, 103 adverse events occurred, including one serious adverse event and 46 infections. In 38 (95%) of 40 patients in the placebo group, 87 adverse events occurred, including four serious adverse events and 49 infections. INTERPRETATION: On the basis of this trial, we cannot recommend abatacept treatment as standard of care to reduce systemic disease activity in patients with primary Sjögren's syndrome. Further studies should evaluate whether patients with specific clinical manifestations and biological characteristics might benefit from abatacept treatment. FUNDING: Bristol-Myers Squibb.
引用
- van Nimwegen JF, Mossel E, van Zuiden GS, et al. Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study). Lancet Rheumatol. 2020. PMID: 38263653. doi:10.1016/S2665-9913(19)30160-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。